Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Kiyoi

Showing results (31-40 of 270) with videos related to

Pageof 27
Sort By:
Biochemical and Biophysical Research Communications|May 30, 2006
Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivoAkihide Atsumi, Akihiro Tomita, Hitoshi Kiyoi, et al.
Scientific Reports|March 7, 2018
Analysis of the oligomeric states of nucleophosmin using size exclusion chromatographyGyosuke Sakashita, Hitoshi Kiyoi, Tomoki Naoe, et al.
British Journal of Haematology|March 29, 2014
Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expressionKazuyuki Shimada, Akihiro Tomita, Shigeki Saito, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|October 16, 2008
[FLT3 tyrosine kinase inhibitors: current status and future perspectives for their development]Shiro Akinaga, Yukimasa Shiotsu, Hitoshi Kiyoi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 12, 2025
Induction of T-Cell Differentiation by KLF4 in T-Cell Acute Lymphoblastic Leukemia Cells Harboring Activating Mutation in NOTCH3Mina Noura, Takahiko Yasuda, Hitoshi Kiyoi, et al.
International Journal of Hematology|March 25, 2020
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML)Hitoshi Kiyoi, Hiroki Yamaguchi, Yoshinobu Maeda, et al.
European Journal of Haematology|December 1, 2011
Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-cateninTomohiro Kajiguchi, Akira Katsumi, Ryohei Tanizaki, et al.
Oncotarget|June 23, 2016
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cellsFangli Chen, Yuichi Ishikawa, Akimi Akashi, et al.
Oncogene|April 24, 2002
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domainHitoshi Kiyoi, Ryuzo Ohno, Ryuzo Ueda, et al.
Cancer Medicine|June 28, 2024
NUP98-BPTF promotes oncogenic transformation through PIM1 upregulationMina Noura, Sakura Tomita, Takahiko Yasuda, et al.
Pageof 27

Showing results (31-40 of 270) with videos related to

Sort By:
Pageof 27
Biochemical and Biophysical Research Communications|May 30, 2006
Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivoAkihide Atsumi, Akihiro Tomita, Hitoshi Kiyoi, et al.
Scientific Reports|March 7, 2018
Analysis of the oligomeric states of nucleophosmin using size exclusion chromatographyGyosuke Sakashita, Hitoshi Kiyoi, Tomoki Naoe, et al.
British Journal of Haematology|March 29, 2014
Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expressionKazuyuki Shimada, Akihiro Tomita, Shigeki Saito, et al.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|October 16, 2008
[FLT3 tyrosine kinase inhibitors: current status and future perspectives for their development]Shiro Akinaga, Yukimasa Shiotsu, Hitoshi Kiyoi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 12, 2025
Induction of T-Cell Differentiation by KLF4 in T-Cell Acute Lymphoblastic Leukemia Cells Harboring Activating Mutation in NOTCH3Mina Noura, Takahiko Yasuda, Hitoshi Kiyoi, et al.
International Journal of Hematology|March 25, 2020
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML)Hitoshi Kiyoi, Hiroki Yamaguchi, Yoshinobu Maeda, et al.
European Journal of Haematology|December 1, 2011
Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-cateninTomohiro Kajiguchi, Akira Katsumi, Ryohei Tanizaki, et al.
Oncotarget|June 23, 2016
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cellsFangli Chen, Yuichi Ishikawa, Akimi Akashi, et al.
Oncogene|April 24, 2002
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domainHitoshi Kiyoi, Ryuzo Ohno, Ryuzo Ueda, et al.
Cancer Medicine|June 28, 2024
NUP98-BPTF promotes oncogenic transformation through PIM1 upregulationMina Noura, Sakura Tomita, Takahiko Yasuda, et al.
Pageof 27